ArticleInnovations in pharmacy2022
An Evaluation of Local Pharmaceutical Manufacturing in Zimbabwe: How Prepared is Zimbabwe to Produce COVID-19 Vaccines?
Article in Innovations in pharmacy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Equitable access to the COVID-19 vaccines in Africa (ECOVA) findings from a qualitative enquiry in Zimbabwe.Frontiers in health services · 2026Article
- Increasing challenges of malaria control in sub-Saharan Africa: Priorities for public health research and policymakers.Annals of medicine and surgery (2012) · 2022Article
- The need for a functional pharmaceutical industry in Sierra Leone: lessons from the COVID-19 pandemic.Journal of pharmaceutical policy and practice · 2022Article
- The Urgent Need to Intensify Vaccine Development and Manufacturing in Africa: Lessons from Emerging Pandemics.Innovations in pharmacy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, the COVID-19 pandemic has had a significant impact, given the rise in the demand for novel therapeutics such as vaccines that can be used in the treatment of COVID-19 patients. Compared to other regions of the world, gross vaccine inequity exists in Africa due to several factors tied to the acute lack of vaccines in the region. As a result, efforts are currently being made to ramp up the production of COVID-19 vaccines in the region. However, there are concerns that most countries in Africa lack the adequate pharmaceutical manufacturing capacity required to produce COVID-19 vaccines, and Zimbabwe is not an exception. This article, therefore, aims to evaluate the preparedness and readiness efforts of the Zimbabwean pharmaceutical industry in the production of COVID-19 vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.